Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study
Language English Country Austria Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Speech Acoustics MeSH
- Dopamine Agents therapeutic use MeSH
- Adult MeSH
- Levodopa therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Parkinson Disease complications drug therapy physiopathology MeSH
- Speech Disorders drug therapy etiology physiopathology MeSH
- Speech drug effects MeSH
- Aged MeSH
- Severity of Illness Index MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Dopamine Agents MeSH
- Levodopa MeSH
Although speech dysfluencies have been hypothesized to be associated with abnormal function of dopaminergic system, the effects of dopaminergic medication on speech fluency in Parkinson's disease (PD) have not been systematically studied. The aim of the present study was, therefore, to investigate the long-term effect of dopaminergic medication on speech fluency in PD. Fourteen de novo PD patients with no history of developmental stuttering and 14 age- and sex-matched healthy controls (HC) were recruited. PD subjects were examined three times; before the initiation of dopaminergic treatment and twice in following 6 years. The percentage of dysfluent words was calculated from reading passage and monolog. The amount of medication was expressed by cumulative doses of L-dopa equivalent. After 3-6 years of dopaminergic therapy, PD patients exhibited significantly more dysfluent events compared to healthy subjects as well as to their own speech performance before the introduction of dopaminergic therapy (p < 0.05). In addition, we found a strong positive correlation between the increased occurrence of dysfluent words and the total cumulative dose of L-dopa equivalent (r = 0.75, p = 0.002). Our findings indicate an adverse effect of prolonged dopaminergic therapy contributing to the development of stuttering-like dysfluencies in PD. These findings may have important implication in clinical practice, where speech fluency should be taken into account to optimize dopaminergic therapy.
See more in PubMed
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 PubMed
Expert Opin Pharmacother. 2004 Jul;5(7):1565-71 PubMed
J Speech Lang Hear Res. 2003 Aug;46(4):1009-15 PubMed
Neuroreport. 1997 Feb 10;8(3):767-70 PubMed
J Speech Hear Disord. 1978 Feb;43(1):47-57 PubMed
Brain Lang. 2013 Sep;126(3):263-78 PubMed
Folia Phoniatr Logop. 2011;63(4):187-94 PubMed
PLoS One. 2012;7(2):e32132 PubMed
Mov Disord. 2001 Jan;16(1):114-8 PubMed
Am J Psychiatry. 1991 Oct;148(10):1309-16 PubMed
J Acoust Soc Am. 2013 Sep;134(3):2171-81 PubMed
J Commun Disord. 2004 Jul-Aug;37(4):325-69 PubMed
J Speech Lang Hear Res. 2007 Aug;50(4):899-912 PubMed
Neuroscience. 2006 Apr 28;139(1):263-76 PubMed
J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):805-7 PubMed
Brain Res. 1987 Aug 25;418(2):262-72 PubMed
N Engl J Med. 2006 Aug 31;355(9):896-908 PubMed
J Neural Transm (Vienna). 2006 May;113(5):625-31 PubMed
Brain. 2008 Jan;131(Pt 1):50-9 PubMed
Brain Lang. 2008 Feb;104(2):190-9 PubMed
Curr Opin Otolaryngol Head Neck Surg. 2008 Jun;16(3):205-10 PubMed
Mov Disord. 2012 Jan;27(1):8-30 PubMed
Mov Disord. 2001 May;16(3):562-5 PubMed
J Fluency Disord. 2003 Spring;28(1):55-70 PubMed
J Acoust Soc Am. 2011 Jan;129(1):350-67 PubMed
J Neural Transm (Vienna). 2009 Feb;116(2):167-9 PubMed
Parkinsonism Relat Disord. 2013 Mar;19(3):383-4 PubMed
J Neurol Neurosurg Psychiatry. 1999 Jun;66(6):776-8 PubMed
Arch Neurol. 1983 Mar;40(3):175-7 PubMed
J Commun Disord. 1996 Nov-Dec;29(6):471-7; quiz 477-8 PubMed
Mov Disord. 2008 Mar 15;23(4):574-80 PubMed
Speech and gait abnormalities in motor subtypes of de-novo Parkinson's disease
